Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,631 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sirolimus-eluting or everolimus-eluting stents for coronary artery disease: 5-year outcomes of the randomised BIOFLOW-IV trial.
Slagboom T, Toelg R, Witzenbichler B, Haude M, Masotti M, Ruiz Salmeron R, Witkowski AR, Uematus M, Takahashi A, Waksman R, Saito S. Slagboom T, et al. Among authors: saito s. EuroIntervention. 2023 Feb 20;18(14):1197-1200. doi: 10.4244/EIJ-D-22-00526. EuroIntervention. 2023. PMID: 36625005 Free PMC article. Clinical Trial. No abstract available.
Comparison of frequency of radial artery occlusion after 4Fr versus 6Fr transradial coronary intervention (from the Novel Angioplasty USIng Coronary Accessor Trial).
Takeshita S, Asano H, Hata T, Hibi K, Ikari Y, Kan Y, Katsuki T, Kawasaki T, Masutani M, Matsumura T, Premchand RK, Rao SP, Suzuki T, Takahashi A, Takeda R, Tanaka S, Yamazaki S, Yin WH, Yoshimachi F, Saito S; NAUSICA Trial Investigators. Takeshita S, et al. Among authors: saito s. Am J Cardiol. 2014 Jun 15;113(12):1986-9. doi: 10.1016/j.amjcard.2014.03.040. Epub 2014 Apr 1. Am J Cardiol. 2014. PMID: 24786357 Clinical Trial.
Incidence and predictors of unplanned non-target lesion revascularisation up to three years after drug-eluting stent implantation: insights from a pooled analysis of the RESOLUTE Global Clinical Trial Program.
Abdel-Wahab M, Neumann FJ, Serruys P, Silber S, Leon M, Mauri L, Yeung A, Belardi JA, Widimský P, Meredith I, Saito S, Richardt G. Abdel-Wahab M, et al. Among authors: saito s. EuroIntervention. 2016 Jul 20;12(4):465-72. doi: 10.4244/EIJY15M07_07. EuroIntervention. 2016. PMID: 26477642 Free article. Clinical Trial.
Bioresorbable polymer sirolimus-eluting coronary stent compared with permanent polymer everolimus-eluting coronary stent implantation for treatment of small vessel coronary artery disease: CENTURY II trial.
Wöhrle J, Markovic S, Rottbauer W, Muramatsu T, Kadota K, Vázquez-González N, Odenstedt J, Serra A, Antoniucci D, Varenne O, Saito S, Wijns W. Wöhrle J, et al. Among authors: saito s. EuroIntervention. 2016 Jun 12;12(2):e167-74. doi: 10.4244/EIJV12I2A30. EuroIntervention. 2016. PMID: 27290676 Free article. Clinical Trial.
Comparison of a new slender 6 Fr sheath with a standard 5 Fr sheath for transradial coronary angiography and intervention: RAP and BEAT (Radial Artery Patency and Bleeding, Efficacy, Adverse evenT), a randomised multicentre trial.
Aminian A, Saito S, Takahashi A, Bernat I, Jobe RL, Kajiya T, Gilchrist IC, Louvard Y, Kiemeneij F, Van Royen N, Yamazaki S, Matsukage T, Rao SV. Aminian A, et al. Among authors: saito s. EuroIntervention. 2017 Aug 4;13(5):e549-e556. doi: 10.4244/EIJ-D-16-00816. EuroIntervention. 2017. PMID: 28218605 Clinical Trial.
BIOFLOW-IV, a randomised, intercontinental, multicentre study to assess the safety and effectiveness of the Orsiro sirolimus-eluting stent in the treatment of subjects with de novo coronary artery lesions: primary outcome target vessel failure at 12 months.
Saito S, Toelg R, Witzenbichler B, Haude M, Masotti M, Salmeron R, Witkowski A, Uematsu M, Takahashi A, Waksman R, Slagboom T. Saito S, et al. EuroIntervention. 2019 Dec 6;15(11):e1006-e1013. doi: 10.4244/EIJ-D-18-01214. EuroIntervention. 2019. PMID: 31235458 Free article. Clinical Trial.
Efficacy and Safety of Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin, Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization of Patients With Diabetes Mellitus.
Waksman R, Shlofmitz E, Windecker S, Koolen JJ, Saito S, Kandzari D, Kolm P, Lipinski MJ, Torguson R. Waksman R, et al. Among authors: saito s. Am J Cardiol. 2019 Oct 1;124(7):1020-1026. doi: 10.1016/j.amjcard.2019.06.021. Epub 2019 Jul 15. Am J Cardiol. 2019. PMID: 31353004
7,631 results